AbbVie | ABBV

Stock Price
212.56
Daily Change
-0.44 -0.21%
Monthly
8.28%
Yearly
9.95%
Q3 Forecast
210.80

Peers Price Chg Day Year Date
Eisai 5,137.00 125.00 2.49% -11.57% Sep/05
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Abbott 132.94 0.13 0.10% 16.68% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Bristol-Myers Squibb 47.14 0.45 0.96% -3.28% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Medtronic 92.93 0.13 0.14% 3.32% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
UCB 206.90 2.30 1.12% 28.99% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Zoetis 153.32 0.12 0.08% -19.13% Sep/05

Indexes Price Day Year Date
US500 6481 -20.59 -0.32% 19.84% Sep/05

AbbVie traded at $212.56 this Friday September 5th, decreasing $0.44 or 0.21 percent since the previous trading session. Looking back, over the last four weeks, AbbVie lost 8.28 percent. Over the last 12 months, its price rose by 9.95 percent. Looking ahead, we forecast AbbVie to be priced at 210.80 by the end of this quarter and at 205.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.